XPhyto Therapeutics Corp. News

XPhyto Therapeutics Announces Private Placement

January 5, 2021 (Source) — XPhyto Therapeutics Corp. (CSE:XPHY) (OTC:XPHYF) (FSE:4XT) (“XPhyto” or the “Company“), is pleased to announce a non-brokered […]


XPhyto Completes Successful SARS-CoV-2 RT-PCR Diagnostic Test Kit Validation

December 17, 2020 (Source) — XPhyto Therapeutics Corp. (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) (“XPhyto” or the “Company“), a next-generation bioscience accelerator, and […]


XPhyto Therapeutics Closes Investment

December 8, 2020 (Source) — XPhyto Therapeutics Corp. (CSE:XPHY) (OTC:XPHYF) (FSE:4XT) (“XPhyto” or the “Company“), is pleased to announce that it has […]


XPhyto Therapeutics Announces Investment

December 3, 2020 (Source) — NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED […]


XPhyto Secures Exclusive Psychedelic Drug Development Agreement

November 10, 2020 (Source) — Psilocybin, mescaline, LSD, MDMA, DMT and other psychedelic compounds added to exclusive dealing agreement for […]


RE-TRANSMISSION: XPhyto Appoints European Healthcare Executive to Board of Directors

November 5, 2020 (Source) — Experienced pharma executive and consultant Per S. Thoresen joins board Advisory engagement with CorpCann AS […]